Core Viewpoint - Chronic kidney disease (CKD) is a significant and worsening non-communicable disease globally, affecting 8%-14% of adults, leading to increased risks of end-stage kidney disease (ESKD) and cardiovascular events [1][2] Group 1: Disease Impact and Statistics - CKD patients face a significantly increased risk of ESKD and major cardiovascular events, resulting in approximately 2.6 million deaths annually, with 960,000 deaths attributed to ESKD [1] - Hyperuricemia is a common and modifiable complication in CKD patients, with a prevalence twice that of the general population, and its incidence rises sharply with the progression of kidney disease [1][4] Group 2: Research Findings - A recent multicenter real-world study published in "Signal Transduction and Targeted Therapy" demonstrated that urate-lowering therapy (ULT) significantly reduces the risk of kidney function loss and all-cause mortality in CKD patients with hyperuricemia, regardless of gout attacks [2][4] - The study included 269,831 eligible participants, with a primary outcome of composite kidney outcomes defined by a decline in estimated glomerular filtration rate (eGFR) of over 40% or ESKD [5] Group 3: Treatment Outcomes - The cumulative incidence of composite kidney outcomes over three years was 19.69% in the ULT group compared to 23.22% in the control group, indicating a risk difference of -3.53% [5] - The estimated risk differences for ESKD, all-cause mortality, and cardiovascular mortality over three years were -1.88%, -2.25%, and -0.69%, respectively, all favoring the ULT group [5][7]